Tempus AI Inc
investors.tempus.comWhat Do They Do?
Provides genomic and other laboratory tests linked to patient clinical data, plus data and clinical-trial services for healthcare providers, drug companies and researchers.
10-K for FY2025, filed Feb 24, 2026
How Do They Make Money?
For clinical tests, Tempus is paid by Medicare, Medicaid and commercial insurers after claims are processed, generally 30-120 days after service; direct-bill customers usually pay 30-60 days after invoice. Drug and biotechnology customers pay for data licenses and clinical-trial services, generally 60 to 90 days after service.
10-K for FY2025, filed Feb 24, 2026For clinical orders from Medicare, Medicaid, and commercial insurance, the Company determines transaction price by reducing the standard…View ↗
For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction…View ↗
Data and applications revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical…View ↗
For Insights, Trials and Next arrangements, pricing is fixed and the Company may be compensated through a combination of an upfront payment…View ↗
-
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗
$1.3B
-
10-K for FY2025, filed Feb 24, 2026
$1.3B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Diagnostics
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
75% |
Diagnostics, FY2025
$955.4M Sources
|
Sold outright |
|
Data and applications
|
25% |
Data and applications, FY2025
$316.4M Sources
|
Who Are Their Customers?
Physicians and genetic counselors order lab tests; pharmaceutical and biotechnology companies buy data and clinical-trial services directly, while research institutions and other third parties buy lab services.
10-K for FY2025, filed Feb 24, 2026The Company derives revenue from selling lab services (“Diagnostics”) to physicians, genetic counselors, academic research institutions…View ↗
The Company generally recognizes revenue for its Diagnostics product offering when it has met its performance obligation relating to an…View ↗
For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction…View ↗
Data and applications revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical…View ↗
Do Revenues Turn Into Profits?
No. It lost $245M in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 30, 2026
$5.6MView ↗
- ▲ Now profitable
- vs −$42.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Jul 30, 2026
Open tableView ↗
-
Jul 30, 2026
Raised revenue guidance
Raised its 2026 revenue guidance to $1.595 to $1.605 billion.
Sources
8-K, filed Jul 30, 2026
Tempus is increasing its full year 2026 revenue guidance to $1.595 to $1.605 billion, which represents ~25% annual growth. We continue to…View ↗
-
Jul 20, 2026
Agreed to acquire Personalis
Personalis would become a wholly owned Tempus subsidiary if the merger closes.
Sources
8-K, filed Jul 20, 2026
On July 20, 2026, Tempus AI, Inc., a Nevada corporation (“Tempus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)…View ↗
Who Do They Compete With?
Competes with Foundation Medicine, Roche Holdings, Caris Life Sciences, Guardant Health, Natera, Neogenomics, ResolutionBio, Agilent, Quest, LabCorp, Myriad Genetics, Genomind, GeneDx, Variantyx, Baylor Genetics, Flatiron Health, IQVIA Holdings, ConcertAI, Fortrea, and ICON
10-K for FY2025, filed Feb 24, 2026Our Diagnostics product line primarily faces competition from diagnostics companies that profile genes in cancers and other disease areas…View ↗
Loading...
